These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7010166)

  • 21. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
    Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of heparin and prostacyclin/heparin infusion on platelet aggregation in hemodialyzed patients.
    Kuźniewski M; Sułowicz W; Hanicki Z; Kus J; Nowogrodzka-Zagórska M; Kostka-Trabka E; Bieroń K; Debińska-Kieć A
    Nephron; 1990; 56(2):174-8. PubMed ID: 2243573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis.
    Ylikorkala O; Huttunen K; Järvi J; Viinikka L
    Clin Nephrol; 1982 Aug; 18(2):83-7. PubMed ID: 6754193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.
    Chanard J; Lavaud S; Maheut H; Kazes I; Vitry F; Rieu P
    Nephrol Dial Transplant; 2008 Jun; 23(6):2003-9. PubMed ID: 18156457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
    van Wyk V; Badenhorst PN; Kotzé HF
    Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostacyclin as the sole antithrombotic agent for acute renal failure hemodialysis.
    Hory B; Saint-Hillier Y; Perol JC
    Nephron; 1983; 33(1):71. PubMed ID: 6339968
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxical behaviour of antithrombin III during hemodialysis and its prevention with prostacyclin.
    Turney JH; Fewell M; Williams LC; Dodd N; Weston MJ
    Clin Nephrol; 1982 Jan; 17(1):31-5. PubMed ID: 7035043
    [No Abstract]   [Full Text] [Related]  

  • 31. Extracorporeal management of acute renal failure patients at high risk of bleeding.
    Ward DM; Mehta RL
    Kidney Int Suppl; 1993 Jun; 41():S237-44. PubMed ID: 8320930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin elimination and hemostasis in hemodialysis.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of heparin anticoagulation for hemodialysis.
    Davenport A
    Hemodial Int; 2011 Oct; 15 Suppl 1():S43-8. PubMed ID: 22093600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].
    Kozlova TV; Shilo VIu; Denisov AIu
    Klin Med (Mosk); 2005; 83(9):45-9. PubMed ID: 16279040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional citrate anticoagulation for single-needle hemodialysis: a prospective clinical study.
    Gubensek J; Buturovic-Ponikvar J; Ponikvar R
    Blood Purif; 2007; 25(5-6):454-6. PubMed ID: 18057876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
    Nowak G; Bucha E; Brauns I; Czerwinski R
    Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure.
    Davenport A; Will EJ; Davison AM
    Nephron; 1994; 66(4):431-7. PubMed ID: 8015647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil adhesiveness during prostacyclin and heparin hemodialysis.
    Spagnuolo PJ; Bass SH; Smith MC; Danviriyasup K; Dunn MJ
    Blood; 1982 Oct; 60(4):924-9. PubMed ID: 7052162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study.
    Fabbri LP; Nucera M; Al Malyan M; Becchi C
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):92-7. PubMed ID: 19650808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developments in dialysis for acute renal failure.
    Richards NT; Mansell MA
    Br J Hosp Med; 1986 Mar; 35(3):190-2. PubMed ID: 3527316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.